SC-236

C₁₆H₁₁ClF₃N₃O₂S

401.79

MFCD00941297

329823698

NA.77

SC-236 has been used as a COX-2 inhibitor to study its effects on the mechano-reflex in rats.

SC-236 exhibits anti-tumor activity in gastric cancer cells by modulating activator protein-1 (AP-1) expression and by blocking the anchorage-independent cell growth. It also exhibits a protective effect against cartilage damage by minimizing the inflammation and pain in osteoarthritis. It is also reported to treat allergic inflammation.
SC-236 is a cyclooxygenase-2 (COX-2) inhibitor.

This compound was developed by Pfizer for Lipid Signaling research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sold for research purposes under agreement from Pfizer Inc.
Pfizer is a registered trademark of Pfizer, Inc.

100

≥98% (HPLC)

powder

Pfizer^®

white to off-white

DMSO: >20 mg/mL

Pfizer

2-8℃

NS(=O)(=O)c1ccc(cc1)-n2nc(cc2-c3ccc(Cl)cc3)C(F)(F)F

1S/C16H11ClF3N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)

NSQNZEUFHPTJME-UHFFFAOYSA-N

5, 25 mg in glass bottle

GHS06

Danger

H301

P301 + P310

Acute Tox. 3 Oral

6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK 3